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The factitive role of Mycobacterium avium ss. paratuberculosis (MAP) in Crohn’s disease
has been debated for more than a century. The controversy is due to the fact that Crohn’s
disease is so similar to a disease of MAP-infected ruminant animals, Johne’s disease; and,
though MAP can be readily detected in the infected ruminants, it is much more difficult
to detect in humans. Molecular techniques that can detect MAP in pathologic Crohn’s
specimens as well as dedicated specialty labs successful in culturing MAP from Crohn’s
patients have provided strong argument for MAP’s role in Crohn’s disease. Perhaps more
incriminating for MAP as a zoonotic agent is the increasing number of diseases with which
MAP has been related: Blau syndrome, type 1 diabetes, Hashimoto thyroiditis, and multiple
sclerosis. In this article, we debate about genetic susceptibility to mycobacterial infection
and human exposure to MAP; moreover, it suggests that molecular mimicry between pro-
tein epitopes of MAP and human proteins is a likely bridge between infection and these
autoimmune disorders.
Keywords: paratuberculosis, MAP, Crohn’s, autoimmune, molecular mimicry, type 1 diabetes, autoimmune
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INTRODUCTION
In 1913, a concise description of what today is known as Crohn’s
disease was offered by Scottish surgeon Kennedy Dalziel (1).
Twenty years earlier, in 1895, German veterinary Johne H. A.
described the cause of an incurable profuse diarrhea in cattle.
He noted acid-fast bacteria (most often indicating the organ-
ism that causes tuberculosis) that, when transferred to a guinea
pig, did not cause tuberculosis (2). Johne first labeled the dis-
ease “pseudotuberculosis” and it eventually became known as
paratuberculosis.
Infected cow’s intestines had the same cobblestone aspect of
Dalziel’s patient and microscopically, the patient’s and cattle’s dis-
eased intestines were so alike that Dalziel wrote that the tissue
characteristics were:
. . . so similar as to justify a proposition that the diseases may
be the same (1).
He hypothesized that the disease in cattle and the disease in peo-
ple shared the same cause. The disease in humans was later named
after Dr. Crohn who described a series of patients in 1932 (3).
The heart of this 100-year controversy revolves around the
fact that the usual diagnostic techniques to detect bacteria are
commonly inefficacious to detect Mycobacterium avium ss. paratu-
berculosis (MAP) in humans. A short explanation is that it is just
very difficult to grow MAP from humans; and, MAP exists with
a modified cell wall – the component of the bacterium that takes
up the characteristic acid stain. In this state, the bacterium is no
longer “acid fast” and cannot be detected microscopically. Recent
work has identified the capacity of MAP to undergo a morphologic
change to become spore-like. The spore morphotype survives heat
and other stressors and may lead to an increased persistence in
hosts and the environment (4).
Understanding the difficulty in detection and appreciating the
work of specialty labs that have shown MAP bacteremia in Crohn’s
disease patients, there has been a warming to the association of
MAP in Crohn’s (5).
MYCOBACTERIUM AVIUM ss. PARATUBERCULOSIS
Mycobacterium avium ss. paratuberculosis is an acid-fast stain-
ing small rod-shaped bacterium (6, 7). As with members of the
Mycobacteriaceae genus, its cell wall structure rich in complex
lipids is unique. The tough and peculiar cell wall of mycobacteria
is, in large part, responsible for the persistence of these bacteria,
both in the environment and inside the host. Paradoxically, the
pathogenic potential of mycobacteria increases as their growth
rate decrease. In fact, slow-growing mycobacteria are more path-
ogenic than fast growing mycobacteria. Except the uncultivable
Mycobacterium leprae (the cause of leprosy in humans), MAP
has the slowest growth rate among harmful mycobacteria. After
inoculum of infected samples from infected animals and incu-
bated under optimal conditions, MAP colonies usually appear not
before 3 months or more (8).
MAP AND HUMAN EXPOSURE
Mycobacterium avium ss. paratuberculosis can be found in pas-
teurized milk (9, 10), milk powder for children (11), surface water
(12–14), soil (12), cow manure that contaminates the soil and
surface water, moreover cow manure is usually applied as fertil-
izer in different crops (15) and supply of drinking water (16) all
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contributing to human exposure. Soil and plants in grazing areas
retain MAP; its DNA can be detected in the upper greens of plants,
their roots and in the soil below the roots to a depth of 80 cm (17,
18). MAP DNA was detected in over 80% of domestic water sam-
ples in Ohio (19). Chlorination and filtration may help to survive
mycobacteria rather than eliminate these organisms by killing off
their competitors (20). Moreover, mycobacteria organisms have
been reported on tap water pipes (21) in biofilms (22) and plas-
tic water bottles (23). One estimate is that mycobacteria could be
present in drinking water in “massive numbers,” on the amount of
up to 700,000 or 7× 105 organisms per liter of water (22). A recent
study reported testing infant formula for MAP in 65 samples from
18 countries: >40% tested positive for viable MAP (24).
MAP AND HUMAN DISEASES
In addition to Crohn’s, MAP has been associated with multiple
diseases: sarcoidosis and Blau syndrome (25), type 1 diabetes (26–
32), Hashimoto’s thyroiditis (33–36), and multiple sclerosis (MS)
(37–49). In autoimmune diabetes, thyroiditis, and MS, MAP is
thought to induce pathology due to molecular mimicry between
protein elements of itself and the targeted organ elements of the
host, e.g., MAP 3865c and Znt8 in autoimmune (type 1) diabetes
and thyroiditis (31, 35, 36). Figure 1 shows how MAP may trigger
autoimmune diseases.
If humans are so readily exposed to MAP, why is there not per-
vasive Crohn’s disease and the other diseases mentioned in this
article?
GENETICS
CARD15
A good example about the interaction between the genetic
susceptibility and microbial infection can be found in Crohn’s
and Blau syndrome (50), both having polymorphisms within the
CARD15 gene.
The gene was originally referred as the NOD2 gene and link-
age studies have placed it on chromosome 16; now it is known as
the CARD15 gene (51). The CARD15 gene is part of the ancestral
innate immune system that recognizes bacteria peptidoglycan in
particular mycobacterial glycolylated form of muramyl dipeptide
MDP (52–54).
CARD15, BLAU SYNDROME, AND CROHN’S DISEASE
Insights into the consequence of genetic susceptibility to MAP
infection may be observed in the rare inflammatory disease, Blau
syndrome. This granulomatous inflammatory disorder is charac-
terized by uveitis, arthritis, and dermatitis (50). Although rare,
Blau syndrome has been of interest in recent medical literature
because of the inherited or de novo mutation within the CARD15
gene, the same gene associated with Crohn’s susceptibility (55,
56). However, Blau syndrome susceptibility component of the
CARD15 gene is located at the nucleotide binding site domain
(55, 56) whereas the Crohn’s susceptibility can be found at the
N-terminal leucine-rich repeat domain (57–59).
Blau syndrome shares the same clinical characteristics of juve-
nile sarcoidosis; in fact, new CARD15 mutations are consistently
found in cases of sporadic juvenile sarcoidosis – Blau syndrome
(60, 61). For these reasons – the clinical appearance of sar-
coidosis and a shared genetic susceptibility with Crohn’s – it
was proposed that MAP could have a role in Blau syndrome.
A series of Blau tissues comprised of skin, synovial samples as
well as Blau graulomas of the liver and kidney were tested for the
presence of MAP. Six tissues of five patients representing three
different families were all found to have MAP present in the tissue
granulomas (25).
FIGURE 1 |The increased spread of Mycobacterium avium ss.
paratuberculosis associated with genetic susceptibility to intracellular
pathogens such as MAP (e.g., CARD15, SLC11A1) is leading to an
increase of autoimmune diseases and inflammatory diseases such as
type 1 diabetes (T1D), Hashimoto thyroiditis (HT), multiple sclerosis
(MS), Crohn’s disease, Blau syndrome, etc. Some of the MAP proteins
involved are indicated (in black) with the human homologous target proteins
(in white).
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The proposed etiopathology is that following MAP exposure,
an individual genetically susceptible with mutations within the
nucleotide binding domain of CARD15 will exhibit Blau syn-
drome whereas if the mutations are within the leucine-rich-repeat
domain of the same gene, they may exhibit Crohn’s disease. More-
over, it has been reported that CARD15 defects of the leucine-
rich-repeat domain, are associated in an aggressive phenotype of
Crohn’s disease (62). Recent work has reviewed the susceptibility
genes associated with Crohn’s (63).
SLC11A1
An additional gene linked with Crohn’s susceptibility is the
solute carrier 11a1 (SLC11A1) gene (64). SLC11A1 was previously
identified as natural resistance-associated macrophage protein 1
(NRAMP1) (65). Polymorphisms within this gene and its pro-
moter are recognized as having a role in the susceptibility of
humans and animals to a number of infections, in particular
mycobacterial infections, and it has been related to the suscep-
tibility to autoimmune and inflammatory disease as well (64, 65).
The SLC11A1 gene, located on chromosome 2q35, is around 14 kb
in length. It encodes an integral membrane protein of 550 amino
acids that is localized within the acidic endosomal and lysosomal
compartment of resting macrophages (65).
The product of the SLC11A1 gene modulates the cellular envi-
ronment in response to activation by intracellular pathogens
by acidifying the phagosome thus killing the pathogen (66).
As such, it plays a role in host innate immunity (67). Muta-
tions of SLC11A1 may impair phagosome acidification yield-
ing a permissive environment for the persistence of intracellular
bacteria (68).
SLC11A1 IN INFECTIOUS AND AUTOIMMUNE DISEASE
Sarcoidosis, an other systemic disease associated with MAP, has
been associated with polymorphisms of the SLC11A1 gene (69).
Susceptibility to mycobacterial diseases, leprosy, and Buruli’s ulcer
were also associated with polymorphism of the SLC11A1 gene
(70). Similar polymorphisms have been associated with Johne’s
disease (paratuberculosis) in cattle (71), goats (72), and sheep
(73). A SLC11A1 defect mouse was created by researchers at the
Belgium Pasteur Institute to develop a murine model for MAP
infection (74).
Due to the capability of SLC11A1 to modulate innate immunity,
it is not surprising that the relationship between polymorphisms
in SLC11A1 and a number of mycobacterial as well as autoimmune
diseases has been explored (75). In addition to leprosy (76) and
tuberculosis (77), an association is found in rheumatoid arthritis
(78), MS (39, 79), inflammatory bowel disease (80–82), and type
1 diabetes – all diseases associated with MAP (83, 84).
MOLECULAR MIMICRY
Molecular mimicry by a microorganisms has been hypothesized to
initiate and exacerbate an autoimmune response through sequence
or structural similarities with self-antigens (85, 86). Rheumatic
fever is one of the best examples for molecular mimicry between
group A streptococcus and host antigens leading to the glomeru-
lonephritis and rheumatic heart disease (87, 88). The development
of post-streptococcal sequelae is characterized by damage to the
heart, joints, and the central nervous system (Sydenham’s chorea).
Damage of the heart is the most critical effect and is present in
30–45% of the cases – mostly causing damage to the heart valves.
MAP AND TYPE 1 DIABETES
Type 1 diabetes mellitus (T1DM) is an autoimmune disease man-
ifest by progressive T cell-mediated autoimmune destruction of
insulin-producing beta cells in the pancreatic islets of Langher-
ans (89). Sechi in 2008 found the DNA of MAP in the blood
of autoimmune (type 1) patients (32) but not non-autoimmune
(type 2) diabetes (27, 28). Sechi also found an association of poly-
morphisms of the SLC11a1 gene and MAP in T1DM patients
(59, 64, 82).
While it may be intuitive to envision an occult presence of
MAP as an infective agent producing a granulomatous lesion of
Crohn’s or sarcoidosis (Table 1A); it may be more difficult to
assign a role for MAP in T1DM. The link connecting MAP and
T1DM is molecular mimicry: protein elements of the pathogen
“look like”elements of the host’s endocrine pancreas; and immune
responses directed at the pathogen sometimes may attack the host
(Table 1B). Childhood exposure to cows milk-based infant for-
mula is a strong risk factor for juvenile autoimmune diabetes (30)
Table 1 | (A) Map-related granulomatous diseases. (B) Map-associated
autoimmune diseases.
(A) MAP-RELATED GRANULOMATOUS DISEASES
Disease Shared genetic
susceptibility
Reference
Crohn’s CARD15, SLC11A1 (8, 51, 52, 57, 59, 62, 64)
Sarcoidosis SLC11A1 (54, 69)
Blau syndrome CARD15 (52–56, 60)
These granulomatous diseases are ones where evidence of MAP can be found in
the granuloma. CARD15, caspase recruitment domain gene 15; SLC11a1, solute
carrier 11a1 gene.
(B) MAP-ASSOCIATED AUTOIMMUNE DISEASES
Disease Mimicking elements Reference
Autoimmune
diabetes
HSP65/GAD (31, 86–88, 90–94)
MAP3865c/ZnT8 –
pancreatic
Autoimmune
thyroiditis
MAP3865c/ZnT8 – thyroid (35, 36)
Multiple
sclerosis
HSP70, MAP_2694,
MAP4027, MAP_2619c
352-61, MAP_0106c
protein 121–132
(37–49)
These autoimmune diseases have autoantibodies. There are share molecular
elements between MAP proteins and host organs. HSP65, heat shock protein
65; GAD, glutamic acid decarboxylase; MAP3865c, M. paratuberculosis protein
3865c; ZnT8, zinc transporter 8; HSP70, heat shock protein 70; MAP-0106c, M.
paratuberculosis 0106c protein (aa. 121–132); MBP85-98, myelin basic protein
(aa. 85–98).
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and, as mentioned in the “exposure to MAP” section of this paper,
viable MAP is found in infant formula (24).
The proposed links is the mimicry of mycobacterial protein
MAP3865c and the human homolog Znt8 (31, 35) along with the
heat shock protein of MAP (HSP65) and pancreatic glutamic acid
decarboxylase (GAD) (30). Different islet autoantibodies (aAbs)
may characterize the period preceding T1D clinical onset, aAbs
against islets antigens such as insulin, glutamic acid decarboxylase
(GAD65), insulinoma associated protein-2, and zinc transporter
8 (ZnT8) may be detectable for months up to years before dis-
ease onset. Sechi et al., for example, reported that anti-MAP and
anti-ZnT8 antibodies (Abs) targeting homologous membrane-
spanning sequences are cross-reactive and capable of eliciting
strong immune responses in T1D adult patients (91). One of
the sequences was also able to elicit a T cell response (95). An
association between MAP and T1D in children was demonstrated
by Cossu et al. (96), Additional evidence of the involvement of
MAP in the early phases at T1D onset appear from two studies
(91, 92) where an association between Abs positive for ZnT8 and
MAP homolog epitopes in Sardinian and Italian children at T1D
onset was demonstrated. Moreover, Sechi et al. (93) reported a
similar high antibody response against insulin epitopes and its
MAP homologous peptides in children; those both at risk for
T1D and at T1D onset. A review on the topic was previously
reported (94).
MAP AND AUTOIMMUNE THYROIDITIS
The most common autoimmune disease associated to T1D is
autoimmune thyroid disease, its frequency is estimated at >90%
among patients with T1D and autoimmune diseases (97). Dif-
ferent articles associate MAP to autoimmune (Hashimoto’s) thy-
roiditis (HT) (33, 34). The same molecular mimicry principle
is suggested as the link between MAP and Znt8, one of the
organ-specific autoantigens of thyroiditis (33–36). Though ZnT8
is primarily expressed in pancreatic islet cells, it is also expressed
in the follicular and para-follicular epithelial cells of the thyroid
gland. In view of the evidence accounting for a cross-recognition
of MAP3865c/ZnT8 homologs sequences in T1D subjects, and
applying the theory which proposes MAP as an HT environmen-
tal trigger (acting trough a molecular mimicry mechanism) (35,
36), it is natural to consider MAP for a causal role in HT. Moreover,
it has been reported that the occurrence of islet aAbs (especially
Znt8) was associated with a positive titer of thyroid peroxidase
antibodies (ATPO) in newly diagnosed adult-onset autoimmune
diabetic patients (98).
HEAT SHOCK PROTEINS
Heat shock proteins (HSPs) are expressed at high level in response
to environmental stress. They stabilize proteins and are involved
in the folding of denatured proteins helping cells survive stress-
ful conditions and promoting recovery (99). HSPs are synthe-
sized to respond to the presence of invading pathogens. However,
pathogens may also produce their HSPs. The increased expres-
sion of both self and infective stress proteins and the extensive
sequence homology between microbial and human HSP (50–
80% amino acid homology of mycobacterial HSP65 and human
HSP60) have led to the concept that HSPs are involved in the
etiology and pathogenesis of many immune-mediated disorders
(100). Antibodies to mycobacterial HSPs have been found in
various autoimmune diseases (101). Just to mention some, the
mycobacterial 65 kDa HSP has been associated to rheumatoid
arthritis (102–104), autoimmune hepatitis (105), primary bil-
iary cirrhosis (106), and systemic sclerosis (107). HSP65 has
been reported in different vasculitis-associated systemic autoim-
mune diseases such as Kawasaki disease (108), Behcet’s disease
(109) Takayasu’s arteritis (110), moreover, Hsp70 has also been
associated with MS (90).
MAP AND MULTIPLE SCLEROSIS
Sechi et al. have published studies implicating MAP in MS (37–39,
41–49). Molecular mimicry and SLC11A1 associations are central
to this association as well (40, 41). MAP has been associated with
Epstein–Barr virus (EBV – thought to be one of the triggers of MS)
(44): peptides of each microorganism (MAP and EBV) cross react
with anti-myelin basic protein (MBP) (43) and interferon regu-
latory factor 5 (IRF5) in MS patients (48). Interferon-beta ther-
apy influence antibody response against MAP (49). An extensive
review on the topic has been previously published (46).
THE FUTURE – MAP AND HUMAN DISEASE
The role of MAP in Crohn’s disease has progressed from con-
troversial to conspicuous to compelling. The century-old striking
similarities existing between Johne’s and Crohn’s diseases on a
tissue level are now validated at cellular and molecular levels
(90). There is an increasing awareness and call for resolution
(111, 112). Improved testing strategies for ruminant herds such as
metabolomic profiling (113) will aid in the public health approach
to animal disease and sources of human exposure. On a limited
basis, Crohn’s disease has been treated successfully with antibi-
otics (114, 115). As the MAP/Crohn’s debate resolves and as more
diseases are linked to MAP, there will likely be a major shift in
the public health approach to MAP and human disease. Early
indications of such a shift are two clinical trials employing anti-
mycobaterial drugs: clarithromycin, rifabutin, and clofazimine.
One is a 60-center trial in Crohn’s disease (116) and another is
the same treatment for MS (117). Positive outcomes from efforts
like these – curing Crohn’s disease and MS with anti-mycobacterial
medication as well as prevent autoimmune diabetes and thyroidi-
tis – will further solidify the role of MAP as a zoonotic agent in
human disease and, perhaps after more than a century, will resolve
this medical controversy.
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